Corcept Completes Enrollment in Phase 4 CATALYST Trial [Yahoo! Finance]
Corcept Completes Enrollment in Phase 4 CATALYST Trial
Levi & Korsinsky, LLP Notifies Shareholders of Corcept Therapeutics Incorporated (CORT) an Upcoming Claims Deadline in a Class Action Settlement
Corcept Therapeutics Incorporated (NASDAQ: CORT) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call